Area of research
Genetics · Cancer Research
Research interest
Research interests include Glioma Diagnosis and Treatment, Cancer Genomics and Diagnostics, RNA modifications and cancer, and Epigenetics and DNA Methylation.
Effective targeting of PDGFRA-altered high-grade glioma with avapritinib
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses
A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer.
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.
Investigative needle core biopsies support multimodal deep-data generation in glioblastoma.
Crowd-sourced benchmarking of single-sample tumor subclonal reconstruction.
Distribution of copy number alterations and impact of chromosome arm call thresholds for meningioma.
N-terminal modification of Histone H3 inhibits H3K27M-mediated loss of H3K27 trimethylation
Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
CTIM-12. DUAL IMMUNE CHECKPOINT BLOCKADE FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES
Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort
Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors
Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort.
Aberrant DNA repair reveals a vulnerability in histone H3.3-mutant brain tumors.
Aberrant DNA repair reveals a vulnerability in histone H3.3-mutant brain tumors
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Crowd-sourced benchmarking of single-sample tumor subclonal reconstruction
Germline variation contributes to false negatives in CRISPR-based experiments with varying burden across ancestries.
Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma.
Recurrent breakpoints in the<i>BRD4</i>locus reduce toxicity associated with gene amplification
Author Correction: An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB.
Publisher Correction: Structural variations in cancer and the 3D genome.
Distribution of Copy Number Variants and Impact of Chromosome Arm Call Thresholds for Meningioma
Supplementary Figure S1 from Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma